HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.
Why JAKKS Pacific Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
Barnes & Noble Education, Inc. (NYSE: BNED) jumped 39% to $2.39 after the company posted better-than-expected quarterly sales.
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Oncternal Therapeutics Filed U.S. Patent Application: Combinations Of EFGR Inhibitors And ROR1 Inhibitors For The Treatment Of Cancer
https://www.scribd.com/document/630357588/ONCT-Patent-Application
Benzinga’s Top Ratings Upgrades, Downgrades For December 22, 2022
Upgrades According to DA Davidson, the prior rating for Helen Of Troy Ltd (NASDAQ:HELE) was changed from Neutral…
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib
Agreement is supportive of the planned initiation
HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated
At the European Hematology Association (EHA) meeting, Oncternal Therapeutics Inc (NASDAQ:ONCT) presented initial preclinical results of Oncternal’s ROR1 CAR containing the antigen-binding…